ABSTRACT
INTRODUCTION
Treatment strategies for non-small cell lung cancer (NSCLC) have been revolutionized since the identification of EGFR activating mutations which predict response to EGFR tyrosine kinase inhibitors (TKIs) in 2004 [1, 2] . Over the last decade, various oncogenic driver mutations have been identified in NSCLC, which enables this disease to be classified into clinically relevant molecular subgroups. Large phase III randomized clinical trials have proved the efficacy of targeted therapies over conventional cytotoxic chemotherapy for NSCLC patients harboring EGFR mutations [3] [4] [5] [6] or ALK fusions [7] . In this study, we presented our sequencing results of a comprehensive www.impactjournals.com/oncotarget panel of oncogenic driver mutations in a large prospective series of NSCLC patients who received surgical resection. Figure 1A ). All the seven above-mentioned oncogenic driver mutations were mutually exclusive. We also identified 2 (0.1%) AKT1 mutations, both were E17K mutations. One patient with AKT1 E17K mutation also harbored BRAF V600E mutation; the other did not harbor any of the seven above-mentioned mutations. The identification of FGFR fusions has been reported in our previous study [8] . Six FGFR3-TACC3 fusions were detected out of 1016 lung adenocarcinomas, accounting for a mutation rate of 0.6%.
RESULTS

Frequency of oncogenic driver mutations in NSCLC histologic subtypes
In cases "pan-negative" for mutations in EGFR, HER2, KRAS, BRAF, ALK, ROS1 and RET, we also sequenced for activating mutations in EGFR extracellular domain (ECD), HER2 ECD and transmembrane domain, ERBB3, ARAF and NRG1 (a total of 183 cases for ERBB family genes, and 219 cases for ARAF and NRG1) ( Figure 1B ). Oncogenic EGFR ECD mutations were detected in two cases (1.1%): one was A289D, and the other was R324L. One S310Y mutation and one V659E mutation was detected in HER2 extracellular and transmembrane domain (1.1%), respectively. There was one (0.5%) ARAF S214C mutation. Two (0.9%) CD74-NRG1 fusions were detected. No ERBB3 activating mutations were detected.
In lung squamous cell carcinoma, the mutation rate of EGFR (12 out of 310, 3.9%), KRAS (8 out of 310, 2.6%), HER2 (1 out of 310, 0.3%), BRAF (1 out of 310, 0.3%), ALK (2 out of 310, 0.6%), DDR2 (1 out of 310, 0.3%), AKT1 (1 out of 310, 0.3%), FGFR1 fusions (2 out of 312, 0.6%) and FGFR3 fusions (9 out of 312, 2.9%) has been reported in our previous studies [8, 9] . We sequenced 503 lung squamous cell carcinoma resected from October 2007 to March 2013 for the prevalence of activating FGFR2 and FGFR3 mutations. Six (1.2%) FGFR3 activating mutations were identified, including 5 S249C mutations and 1 R248C mutation (Figure 2A Figure 2C ).
Eight sarcomatoid carcinoma were analyzed for the presence of EGFR kinase domain mutations, KRAS mutations, HER2 kinase domain mutations, BRAF mutations, ALK fusions, RET fusions and AKT1 mutations. Three (37.5%) KRAS mutations were detected, including 2 G12C and 1 G12V ( Figure 2D ).
Clinicopathologic characteristics of NSCLC patients harboring FGFR3 mutations, AKT1 mutations, EGFR ECD mutations, HER2 ECD and transmembrane domain mutations, ARAF mutations or NRG1 fusions
All the 6 lung squamous cell carcinoma patients with oncogenic FGFR3 mutations were male, and 5 of them were ever smokers. They all have tumors larger than 3 cm in diameter (mean: 5.4, range: 3.2-8.0). However, N2 disease was not found in any case (4 N0 and 2 N1). Both of the two adenocarcinoma cases with CD74-NRG1 fusions were female never-smoking stage I invasive mucinous adenocarcinoma. Detailed clinicopathologic characteristics of patients with these rare mutations were listed in Table 1 . Individual characteristics of patients harboring other mutations were showed in Supplementary  Table S1 .
We then compared clinicopathologic characteristics between the 17 lung squamous cell carcinoma patients harboring FGFR fusions or FGFR mutations and 138 lung squamous cell carcinoma cases (both FGFR fusions and FGFR mutations were negative) from October 2007 to April 2010. Age, gender, smoking history, tumor size, nodal status and pathologic stage were not significantly different between the two groups ( Table 2) . RFS (P = 0.562) and OS (P = 0.988) were also comparable ( Figure 3 ).
The effect of EGFR TKIs on EGFR-mutated lung adenocarcinoma patients after disease recurrence
To ensure sufficient follow up, we included patients undergoing surgical resection from October 2007 to March 2012 for survival analysis. RFS of lung adenocarcinoma patients harboring EGFR mutations, KRAS mutations or www.impactjournals.com/oncotarget ALK fusions were compared to that of wild-type patients (Supplementary Figure S1) . No significant survival difference was found. A total of 190 lung adenocarcinoma patients with classic EGFR exon 19 deletions or L858R experienced disease recurrence. Eighty-one of these patients received EGFR TKIs (gefitinib or erlotinib) treatment after disease recurrence. Compared to those who did not receive TKIs, patients who were treated with TKIs had significantly better OS (P < 0.001) ( Figure 4A ). We further performed the survival analysis according to the initial pathologic stage ( Figure 4B and 4C ). Patients treated with targeted therapies had significantly better survival outcomes both in the stage I-II group (P = 0.005) and the stage III group (P < 0.001). Multivariate analysis adjusting for age, sex, smoking history and pathologic stage revealed that treatment with EGFR TKIs was an independent predictor of better OS (HR = 0.299, 95% CI: 0.172-0.519, P < 0.001).
DISCUSSION
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs has been demonstrated to be feasible by the Lung Cancer Mutation Consortium (LCMC) [10] . Here, we performed a comprehensive analysis of oncogenic driver mutations in a large series of Chinese NSCLC patients.
EGFR (15.8%) and KRAS (21.1%) mutations were present in a considerable proportion in lung large cell carcinoma. De Pas and colleagues [11] reported a case of lung large cell carcinoma patient harboring EGFR mutation having dramatic response to gefitinib treatment. We further found that lung sarcomatoid carcinoma had a high frequency (37.5%) of KRAS mutations. Our results have implications for targeted therapy for patients with these rare histologic subtypes of NSCLC.
Liao and colleagues reported in 2013 the identification of inhibitor-sensitive oncogenic FGFR2 and FGFR3 mutations in lung squamous cell carcinoma from the Cancer Genome Atlas (TCGA) dataset [12] . They reported a mutation rate of 3% for each of the two genes. However, we screened more than 500 Chinese lung squamous cell carcinoma samples, and found that oncogenic FGFR3 mutations were present in only 1.2% (5 S249C and 1 R248C). No oncogenic FGFR2 mutations were detected in this series of patients. In addition to the 3.5% (11 out of 312) of FGFR fusions in lung squamous cell carcinoma [8] , approximately 5% of Chinese lung squamous cell carcinoma could be defined by oncogenic alterations in the FGFR family genes. Through clinicopathologic analysis, we also found that patients with oncogenic FGFR3 mutations were characterized by male, smokers, and larger tumor size without mediastinal lymph node metastasis.
Currently, the detection of mutations in ERBB family genes is mainly limited to the kinase domains of EGFR and HER2. However, the identification of oncogenic driver mutations in other sites of the ERBB family genes has continuously been reported [13] [14] [15] [16] [17] . For example, oncogenic HER2 extracellular domain mutations were found in 0.8% (2 out of 258) of lung adenocarcinoma in the TCGA dataset [13] . Jaiswal and colleagues [14] reported oncogenic ERBB3 mutations were present in approximately 1% of lung adenocarcinoma from a Western cohort. Here we found two EGFR ECD mutations (A289D and R324L), one HER2 ECD mutation (S310Y), one HER2 transmembrane domain mutation (V659E) and no ERBB3 activating mutations, suggesting that oncogenic driver mutations in non-EGFR or HER2 kinase domain of ERBB family genes do exist, but in a very small proportion of Chinese lung adenocarcinoma patients.
Imielinski and colleagues [18] reported that oncogenic and sorafenib-sensitive ARAF mutations were present in 1% of lung adenocarcinoma cases in the TCGA samples. NRG1 fusions were also identified as novel oncogenic driver mutations in lung adenocarcinoma [19, 20] . The frequency of NRG1 fusions was reported to be approximately 1.7% in lung adenocarcinomas from an Asian population [20] . Here, we found one ARAF mutation (S214C) and two CD74-NRG1 fusions in 219 "pan-negative" lung adenocarcinoma cases. Both of the two cases with NRG1 fusions were invasive mucinous adenocarcinoma, which was consistent with previous reports that NRG1 fusions were characterized by invasive mucinous adenocarcinoma histology [19, 20] . Targeting oncogenic driver mutations has transformed the management of lung adenocarcinoma patients. Kris and colleagues [10] investigated the presence of oncogenic mutations of 10 genes in more than 1000 lung adenocarcinoma patients, and revealed that patients with an oncogenic driver and received genotype-directed therapy had significantly prolonged survival than those with an oncogenic mutation but did not receive genotype-directed therapy. Here, we investigated the effect of EGFR TKIs on EGFR-mutated lung adenocarcinoma patients after disease recurrence. Compared to those who did not receive TKIs, patients who were treated with TKIs had significantly better OS. Multivariate analysis showed the administration with EGFR TKIs was an independent predictor of better OS. The superiority of EGFR TKIs (including gefitinib, erlotinib and afatinib) over conventional chemotherapy in advanced lung adenocarcinoma has been well demonstrated in Phase III randomized trials [3] [4] [5] [6] 21] .
However, to the best of our knowledge, there is no clinical trial specifically investigating the efficacy of EGFR TKIs in lung cancer patients who have recurrent disease after surgical resection. Our results further supported the role of genotype-directed therapies for lung adenocarcinoma patients.
In conclusion, we determined the frequency of driver mutations in a large series of Chinese NSCLC patients. EGFR TKIs might improve the survival outcomes of EGFR-mutated lung adenocarcinoma patients who experienced disease recurrence. Individual patient data of non-small cell lung cancer harboring oncogenic AKT1  mutations, FGFR3 mutations, EGFR extracellular domain mutations, HER2 extracellular 
MATERIALS AND METHODS
Patients and samples
Statistical analysis
Pearson's chi-squared test or Fisher's exact test was used to investigate correlations between two categorical variables. Independent sample t-test was used to assess associations between one categorical variable and one continuous variable. Kaplan-Meier method with log-rank test was used to compare recurrence-free survival (RFS) and overall survival (OS) in univariate analysis. Cox proportional hazards regression (forward likelihood ratio model) was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) in multivariate survival analysis. The statistical analysis was conducted in SPSS 16.0 (SPSS Inc, Chicago, Ill). All tests were two tailed, and statistical significance was set at P < 0.05.
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